Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX/RT in Squamous Cell Carcinoma of the Anal Canal
NCT00093379Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2004
- Primary completion
- Jul 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in anal cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2004; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
anal cancer
Beyond the preview
Go deeper on NCT00093379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093379.